Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Delcath Systems, Inc. - Common Stock (NQ:DCTH)

15.18 +2.55 (+20.19%)
Streaming Delayed Price Updated: 3:15 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,358,260
Open 14.03
Bid (Size) 15.17 (200)
Ask (Size) 15.19 (1,000)
Prev. Close 12.63
Today's Range 14.00 - 15.62
52wk Range 8.120 - 13.74
Shares Outstanding 7,906,728
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Delcath Systems Q2 Earnings Call Highlights ↗
Delcath Systems (NASDAQ:DCTH) reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and... 
Via MarketBeat
Topics Earnings
News headline image
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire

Performance

YTD
+52.6%
+52.6%
1 Month
+12.6%
+12.6%
3 Month
+34.8%
+34.8%
6 Month
+56.5%
+56.5%
1 Year
+44.3%
+44.3%

More News

Read More
News headline image
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Second Quarter 2026 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems (NASDAQ:DCTH) Surpasses Q1 Estimates, Guidance Points to Continued Growth ↗
Via Chartmill
Delcath Systems Inc (NASDAQ:DCTH) Posts Q4 Beat, Provides Cautious 2026 Outlook ↗
Via Chartmill
News headline image
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath (DCTH) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host First Quarter 2026 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath (DCTH) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire

Frequently Asked Questions

Is Delcath Systems, Inc. - Common Stock publicly traded?
Yes, Delcath Systems, Inc. - Common Stock is publicly traded.
What exchange does Delcath Systems, Inc. - Common Stock trade on?
Delcath Systems, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Delcath Systems, Inc. - Common Stock?
The ticker symbol for Delcath Systems, Inc. - Common Stock is DCTH on the Nasdaq Stock Market
What is the current price of Delcath Systems, Inc. - Common Stock?
The current price of Delcath Systems, Inc. - Common Stock is 15.18
When was Delcath Systems, Inc. - Common Stock last traded?
The last trade of Delcath Systems, Inc. - Common Stock was at 08/06/26 03:15 PM ET
What is the market capitalization of Delcath Systems, Inc. - Common Stock?
The market capitalization of Delcath Systems, Inc. - Common Stock is 120.02M
How many shares of Delcath Systems, Inc. - Common Stock are outstanding?
Delcath Systems, Inc. - Common Stock has 120M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.